Theravance Biopharma
TBPH
TBPH
113 hedge funds and large institutions have $653M invested in Theravance Biopharma in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
14% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 43
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Holders
113
Holding in Top 10
4
Calls
$2.43M
Puts
$947K
Top Buyers
| 1 | +$11.5M | |
| 2 | +$10.4M | |
| 3 | +$9.75M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.98M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$3.53M |
Top Sellers
| 1 | -$10.9M | |
| 2 | -$8.24M | |
| 3 | -$6.57M | |
| 4 |
D.E. Shaw & Co
New York
|
-$6.05M |
| 5 |
Millennium Management
New York
|
-$5.81M |